Related Experiment Video

Updated: Jun 14, 2025

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.3K

Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy

Christoforos Vaxevanis1, Michael Bachmann2, Barbara Seliger3,4,5,6

  • 1Institute for Medical Immunology, Martin Luther University Halle Wittenberg, Halle, Germany.

Journal for Immunotherapy of Cancer
|August 29, 2024
PubMed

Insights

MicroRNAs (miRNAs) are crucial in controlling tumor growth and immune escape. These small non-coding RNAs can serve as biomarkers for cancer diagnosis and prognosis, and as therapeutic targets for improved patient outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • The immune system plays a key role in regulating tumor growth and patient outcomes, particularly with the advent of immunotherapeutics.
  • Tumors frequently evade immune surveillance through various complex mechanisms.
  • Small non-coding RNAs, specifically microRNAs (miRNAs), are increasingly recognized for their essential role in the post-transcriptional regulation of immune modulatory molecules.

Purpose of the Study:

  • To review the multifaceted role of miRNAs in tumor-mediated immune escape.
  • To discuss the potential of miRNAs as diagnostic, prognostic, and predictive biomarkers in cancer.
  • To explore the therapeutic applications of miRNAs in cancer treatment, including novel delivery methods.

Main Methods:

  • Literature review of studies identifying miRNAs targeting key genes in immune escape pathways.
  • Analysis of miRNAs targeting immune checkpoints (e.g., CTLA-4, PD-L1) and other immune response genes.
  • Examination of research on miRNA-based diagnostics, prognostics, and therapeutics.

Main Results:

  • MiRNAs are implicated in post-transcriptional regulation of immune modulatory molecules, influencing tumor immune escape.
  • Identified miRNAs target critical genes such as CTLA-4, PD-L1, and HLA-G, impacting immune recognition.
  • MiRNAs demonstrate potential as biomarkers for discriminating tumor stages and predicting patient outcomes and therapy response.

Conclusions:

  • Immune modulatory miRNAs are pivotal in tumor immune escape and hold significant promise as biomarkers.
  • These miRNAs represent viable therapeutic targets for developing novel cancer treatments.
  • Emerging strategies, including CAR T-cell applications, enhance the therapeutic potential of miRNAs.
Keywords:
Immune Checkpoint InhibitorImmune modulatoryImmunotherapyTumor microenvironment - TME

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.6K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.8K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K